Acrivon (NASDAQ: ACRV) director granted 20,275 stock options at $1.52
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Acrivon Therapeutics director Michael John Tomsicek received a stock option grant covering 20,275 shares of common stock. The option has an exercise price of $1.52 per share and expires on June 16, 2036. All 20,275 option shares are reported as held directly after this grant. The filing states that these options will vest on the date immediately preceding Acrivon’s next annual meeting of stockholders, provided he remains in continuous service through that vesting date. This is a compensation-related award and does not reflect an open-market purchase or sale of shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
TOMSICEK MICHAEL JOHN
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 20,275 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 20,275 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 20,275 shares
Exercise price: $1.52 per share
Expiration date: June 16, 2036
+2 more
5 metrics
Option grant size
20,275 shares
Stock Option (Right to Buy) granted to director
Exercise price
$1.52 per share
Conversion/exercise price of stock option
Expiration date
June 16, 2036
Option expiration for director grant
Holdings after transaction
20,275 option shares
Total derivative shares following grant
Transaction price per option
$0.00
Grant awarded at no cost to director
Key Terms
Stock Option (Right to Buy), Grant, award, or other acquisition, derivative security, exercise price, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
derivative security financial
"transaction_type: "derivative" for the option grant"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
exercise price financial
"conversion_or_exercise_price of $1.5200 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"options vest before the Issuer's next annual meeting of stockholders"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did Acrivon Therapeutics (ACRV) director Michael John Tomsicek report on this Form 4?
He reported receiving a stock option grant for 20,275 shares of Acrivon common stock. The award is compensation-related, giving him the right to buy shares at a fixed price if and when the options vest.
What are the key terms of Michael John Tomsicek’s ACRV stock option grant?
The option covers 20,275 shares of common stock at an exercise price of $1.52 per share. It is a derivative security that expires on June 16, 2036, if not exercised before that date.
When do the ACRV stock options granted to Michael John Tomsicek vest?
The options vest on the date immediately preceding Acrivon’s next annual meeting of stockholders. Vesting is contingent on his continuous service with the company through that specified vesting date.